The PREGVAXGRIP Study: a Cohort Study to Assess Foetal and Neonatal Consequences of In Utero Exposure to Vaccination Against A(H1N1)v2009 Influenza

Chavant, François; Ingrand, Isabelle; Jonville-Béra, Annie Pierre; Plazanet, Caroline; Gras‐Champel, Valérie; Lagarce, Laurence; Zénut, M.; Disson-Dautriche, Anne; Logerot, Sophie; Auffret, Marine; Coubret-Dumas, A.; Bruel, Monserrat; Boyer, M.; Bos-Thompson, MA; Veyrac, G.; Carlier, P.; Beyens, Marie-Noëlle; Lates, S.; Damase‐Michel, Christine; Castot, A; Kreft-Jaïs, Carmen; Pérault‐Pochat, Marie‐Christine

doi:10.1007/s40264-013-0030-1

Cited by 22 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[72] Receipt of different influenza vaccine during pregnancy was not associated with increased or decreased risk of preterm or SGA birth or congenital malformations. [73][74][75] These recent findings support the safety of vaccinating pregnant women against infl uenza during the fi rst, second, and third trimesters.…”

Section: Inf Luenza Treatment and Vaccinationmentioning

confidence: 53%

Prematurity and the burden of influenza and respiratory syncytial virus disease

et al. 2015

View full text Add to dashboard Cite

The particular burden of both viral diseases in preterm infants is dominated by RSV and its associated rehospitalizations during the first two years of life. Prophylactic measures include vaccination against influenza virus of family members and caregivers and active immunization starting at the age of 6 months, and monthly injections of palivizumab during the cold season to avoid severe RSV disease and its sequelae.

show abstract

Section: Inf Luenza Treatment and Vaccinationmentioning

confidence: 53%

Prematurity and the burden of influenza and respiratory syncytial virus disease

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The results are presented in Figure . In total, 100 studies were included in the review . Several studies provided data on maternal morbidity and mortality, pregnancy outcome and treatment.…”

Section: Resultsmentioning

confidence: 99%

Influenza virus infection in pregnancy: a review

Meijer

Noortwijk

Bruinse

et al. 2015

Acta Obstet Gynecol Scand

113

View full text Add to dashboard Cite

show abstract

“…Low uptake reflects poor knowledge among pregnant women of the current recommendations and the excellent safety in pregnancy of current vaccines [42, 43]. Clinical trial data suggests no increased risk of pregnancy complications or adverse fetal outcomes in women immunized in the second or third trimester [44–46] with, if anything, lower risks of premature birth for immunized subjects [47]. Despite more limited data on adjuvanted vaccine safety in pregnancy, widespread use of squalene-adjuvanted vaccines in Europe during the 2009 H1N1 pandemic resulted in significant exposures of pregnant women, with no reports of safety issues [47, 48].…”

Section: Discussionmentioning

confidence: 99%

A single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax™) overcomes pregnancy-associated immune suppression and enhances passive neonatal protection

Honda‐Okubo

Kolpe

et al. 2014

Vaccine

View full text Add to dashboard Cite

Pregnant women and neonates represent high-risk groups for influenza infection, and in general have suppressed responses to standard influenza vaccines due to pregnancy-associated immune suppression and immune system immaturity, respectively. We therefore wished to test whether addition of Advax™, a polysaccharide adjuvant based on delta inulin, to an inactivated influenza vaccine (A/H1N1/PR8) administered during pregnancy would safely enhance vaccine immunogenicity and thereby provide improved protection of pregnant mothers and also potentially their newborns. Pregnant mice received a single intramuscular injection of β-propiolactone inactivated H1N1 antigen alone or with Advax adjuvant. Pregnant dams receiving Advax adjuvanted vaccine exhibited significantly increased serum and breast milk anti-influenza IgG titers. This translated into higher serum anti-influenza IgG titers in the pups of these dams. Complete protection was seen in pups of dams that received Advax-adjuvanted vaccine whereas no survival was seen in pups of control mothers or mothers immunized with unadjuvanted vaccine. Cross-fostering studies confirmed that enhanced protection of pups of dams that received Advax-adjuvanted vaccine was mediated by enhanced transfer of maternal IgG to the pups via breast-feeding. The delta inulin adjuvant was not associated with any reproductive or developmental adverse effects. This study shows that Advax adjuvant was safe when administered with influenza vaccine during pregnancy and provided protection of pups not seen with administration of unadjuvanted vaccine, via enhanced breast milk transfer of anti-influenza antibodies.

show abstract

The PREGVAXGRIP Study: a Cohort Study to Assess Foetal and Neonatal Consequences of In Utero Exposure to Vaccination Against A(H1N1)v2009 Influenza

Cited by 22 publications

References 30 publications

Prematurity and the burden of influenza and respiratory syncytial virus disease

Prematurity and the burden of influenza and respiratory syncytial virus disease

Influenza virus infection in pregnancy: a review

A single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax™) overcomes pregnancy-associated immune suppression and enhances passive neonatal protection

Contact Info

Product

Resources

About